Circulating Tumour Cells and FOXP3 in Regulatory T-Cells as New Modalities in Cancer Diagnosis and Metastasis Location Prediction

Ikhwan Rinaldi

Abstract


Cancer is a complex group of diseases which arises from uncontrolled growth and spread of abnormal cells in the body. The pathophysiology of cancer involves a sequence of events at the cellular and molecular levels, often initiated by genetic mutations or alterations. These mutations can be acquired due to various factors like environmental exposures such as from carcinogens, lifestyle choices, or inherited genetic conditions. When a cell’s DNA is damaged or mutated, it can disrupt the normal regulatory mechanisms that control cell division and apoptosis, leading to uncontrolled proliferation and cancer.

the intricate interplay between genetic mutations, angiogenesis, hematogenic spread, CTCs, immune cells, and systemic cancer therapy defines the complex landscape of cancer progression and treatment. Understanding the role of immune cells, particularly Tregs marked by FOXP3, as prognostic markers in various cancers, alongside advancements in cancer diagnosis involving CTCs, holds promise in understanding cancer prognosis and improving cancer management. Moreover, ongoing research into alleviating chemotherapy-induced side effects, like HFS offer avenues for improving patient care and treatment outcomes in cancer management.


Keywords


tumour cell; FOXP3; T-cells; cancer; circulating tumour cell (CTC)

References


Nishida N, Yano H, Nishida T, Kamura T, Kojiro M. Angiogenesis in Cancer. Vasc Health Risk Manag. 2006;2(3):213–9.

Lugano R, Ramachandran M, Dimberg A. Tumor angiogenesis: causes, consequences, challenges and opportunities. Cell Mol Life Sci. 2020;77(9):1745–70.

Apte RS, Chen DS, Ferrara N. VEGF in signaling and disease: Beyond discovery and development. Cell. 2019;176(6):1248–64.

Lugassy C, Kleinman HK, Cassoux N, Barnhill R. Hematogenous metastasis and tumor dormancy as concepts or dogma? The continuum of vessel co-option and angiotropic extravascular migratory metastasis as an alternative. Front Oncol. 2022;12:996411.

Fares J, Fares MY, Khachfe HH, Salhab HA, Fares Y. Molecular principles of metastasis: a hallmark of cancer revisited. Signal Transduct Target Ther. 2020;5:28.

Wong SY, Hynes RO. Lymphatic or hematogenous dissemination: How does a metastatic tumor cell decide? Cell Cycle Georget Tex. 2006;5(8):812–7.

Li XY, Dong M, Zang XY, et al. The emerging role of circulating tumor cells in cancer management. Am J Transl Res. 2020;12(2):332–42.

Hofman V, Bonnetaud C, Ilie MI, et al. Preoperative circulating tumor cell detection using the isolation by size of epithelial tumor cell method for patients with lung cancer is a new prognostic biomarker. Clin Cancer Res Off J Am Assoc Cancer Res. 2011;17(4):827–35.

Ildiz ES, Gvozdenovic A, Kovacs WJ, Aceto N. Travelling under pressure - hypoxia and shear stress in the metastatic journey. Clin Exp Metastasis. 2023;40(5):375–94.

Donato C, Kunz L, Castro-Giner F, et al. Hypoxia triggers the intravasation of clustered circulating tumor cells. Cell Rep. 2020;32(10):108105.

Chang PH, Chen MC, Tsai YP, et al. Interplay between desmoglein2 and hypoxia controls metastasis in breast cancer. Proc Natl Acad Sci U S A. 2021;118(3):e2014408118.

Millner LM, Linder MW, Valdes R. Circulating tumor cells: A review of present methods and the need to identify heterogeneous phenotypes. Ann Clin Lab Sci. 2013;43(3):295–304.

Harris L, Fritsche H, Mennel R, et al. American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer. J Clin Oncol Off J Am Soc Clin Oncol. 2007;25(33):5287–312.

Lone SN, Nisar S, Masoodi T, et al. Liquid biopsy: a step closer to transform diagnosis, prognosis and future of cancer treatments. Mol Cancer. 2022;21(1):79.

Siravegna G, Marsoni S, Siena S, Bardelli A. Integrating liquid biopsies into the management of cancer. Nat Rev Clin Oncol. 2017;14(9):531–48.

Chan KCA, Jiang P, Chan CWM, et al. Noninvasive detection of cancer-associated genome-wide hypomethylation and copy number aberrations by plasma DNA bisulfite sequencing. Proc Natl Acad Sci U S A. 2013;110(47):18761–8.

Mayers JR, Wu C, Clish CB, et al. Elevation of circulating branched-chain amino acids is an early event in human pancreatic adenocarcinoma development. Nat Med. 2014;20(10):1193–8.

Obermayr E, Reiner A, Brandt B, et al. The long-term prognostic significance of circulating tumor cells in ovarian cancer—A study of the OVCAD consortium. Cancers. 2021;13(11):2613.

Banys-Paluchowski M, Schneck H, Blassl C, et al. Prognostic relevance of circulating tumor cells in molecular subtypes of breast cancer. Geburtshilfe Frauenheilkd. 2015;75(3):232–7.

Cohen SJ, Punt CJA, Iannotti N, et al. Prognostic significance of circulating tumor cells in patients with metastatic colorectal cancer. Ann Oncol Off J Eur Soc Med Oncol. 2009;20(7):1223–9.

Kang BJ, Ra SW, Lee K, et al. Circulating tumor cell number is associated with primary tumor volume in patients with lung adenocarcinoma. Tuberc Respir Dis. 2020;83(1):61–70.

Nguyen TNA, Huang PS, Chu PY, Hsieh CH, Wu MH. Recent progress in enhanced cancer diagnosis, prognosis, and monitoring using a combined analysis of the number of circulating tumor cells (CTCs) and other clinical parameters. Cancers. 2023;15(22):5372.

Shishido SN, Carlsson A, Nieva J, et al. Circulating tumor cells as a response monitor in stage IV non-small cell lung cancer. J Transl Med. 2019;17(1):294.

Li Y, Gong J, Zhang Q, et al. Dynamic monitoring of circulating tumour cells to evaluate therapeutic efficacy in advanced gastric cancer. Br J Cancer. 2016;114(2):138–45.

Li Y, Wu S, Bai F. Molecular characterization of circulating tumor cells-from bench to bedside. Semin Cell Dev Biol. 2018;75:88–97.

Tivey A, Church M, Rothwell D, Dive C, Cook N. Circulating tumour DNA — looking beyond the blood. Nat Rev Clin Oncol. 2022;19(9):600–12.

Ibrahim SF, van den Engh G. Flow cytometry and cell sorting. Adv Biochem Eng Biotechnol. 2007;106:19–39.

Krivacic RT, Ladanyi A, Curry DN, et al. A rare-cell detector for cancer. Proc Natl Acad Sci U S A. 2004;101(29):10501–4.

Ntouroupi TG, Ashraf SQ, McGregor SB, et al. Detection of circulating tumour cells in peripheral blood with an automated scanning fluorescence microscope. Br J Cancer. 2008;99(5):789–95.

Fuchs AB, Romani A, Freida D, et al. Electronic sorting and recovery of single live cells from microlitre sized samples. Lab Chip. 2006;6(1):121–6.

Naoe M, Ogawa Y, Morita J, et al. Detection of circulating urothelial cancer cells in the blood using the CellSearch System. Cancer. 2007;109(7):1439–45.

Disis ML. Immune regulation of cancer. J Clin Oncol. 2010;28(29):4531–8.

Gonzalez H, Hagerling C, Werb Z. Roles of the immune system in cancer: from tumor initiation to metastatic progression. Genes Dev. 2018;32(19–20):1267–84.

Chen B, Khodadoust MS, Liu CL, Newman AM, Alizadeh AA. Profiling tumor infiltrating immune cells with CIBERSORT. Methods Mol Biol Clifton NJ. 2018;1711:243–59.

Li HX, Wang SQ, Lian ZX, Deng SL, Yu K. Relationship between tumor infiltrating immune cells and tumor metastasis and its prognostic value in cancer. Cells [Internet]. 2023 [cited 2023 Dec 21];12(1). Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9818185/

Vihervuori H, Autere TA, Repo H, et al. Tumor-infiltrating lymphocytes and CD8+ T cells predict survival of triple-negative breast cancer. J Cancer Res Clin Oncol. 2019;145(12):3105–14.

Kumar S, Singh SK, Rana B, Rana A. Tumor-infiltrating CD8+ T cell antitumor efficacy and exhaustion: molecular insights. Drug Discov Today. 2021 Apr;26(4):951–67.

Raskov H, Orhan A, Christensen JP, Gögenur I. Cytotoxic CD8+ T cells in cancer and cancer immunotherapy. Br J Cancer. 2021;124(2):359–67.

Sun YP, Ke YL, Li X. Prognostic value of CD8+ tumor infiltrating T cells in patients with breast cancer: A systematic review and meta analysis. Oncol Lett. 2023;25(1):1–11.

Ohue Y, Nishikawa H. Regulatory T (Treg) cells in cancer: Can treg cells be a new therapeutic target? Cancer Sci. 2019;110(7):2080–9.

Koyama S, Nishikawa H. Mechanisms of regulatory T cell infiltration in tumors: implications for innovative immune precision therapies. J Immunother Cancer. 2021;9(7):e002591.

Deng G, Song X, Greene MI. FoxP3 in Treg cell biology: a molecular and structural perspective. Clin Exp Immunol. 2020;199(3):255–62.

Yang S, Liu Y, Li MY, et al. FOXP3 promotes tumor growth and metastasis by activating Wnt/β-catenin signaling pathway and EMT in non-small cell lung cancer. Mol Cancer. 2017;16(1):124.

Saleh R, Elkord E. FoxP3+ T regulatory cells in cancer: Prognostic biomarkers and therapeutic targets. Cancer Lett. 2020;490:174–85.

Jørgensen N, Hviid TVF, Nielsen LB, et al. Tumour-infiltrating CD4-, CD8- and FOXP3-positive immune cells as predictive markers of mortality in BRCA1- and BRCA2-associated breast cancer. Br J Cancer. 2021;125(10):1388–98.

Qiu Y, Ke S, Chen J, et al. FOXP3+ regulatory T cells and the immune escape in solid tumours. Front Immunol [Internet]. 2022 [cited 2023 Dec 21];13. Available from: https://www.frontiersin.org/articles/10.3389/fimmu.2022.982986

Amens JN, Bahçecioglu G, Zorlutuna P. Immune system effects on breast cancer. Cell Mol Bioeng. 2021;14(4):279–92.

Stenström J, Hedenfalk I, Hagerling C. Regulatory T lymphocyte infiltration in metastatic breast cancer—an independent prognostic factor that changes with tumor progression. Breast Cancer Res. 2021;23(1):27.

Usman AN, Ahmad M, Sinrang AW, et al. FOXP3 regulatory T cells on prognosis of breast cancer. Breast Dis. 2023;42(1):213–8.

Bohling SD, Allison KH. Immunosuppressive regulatory T cells are associated with aggressive breast cancer phenotypes: a potential therapeutic target. Mod Pathol Off J U S Can Acad Pathol Inc. 2008;21(12):1527–32.

Jiang D, Gao Z, Cai Z, Wang M, He J. Clinicopathological and prognostic significance of FOXP3+ tumor infiltrating lymphocytes in patients with breast cancer: a meta-analysis. BMC Cancer. 2015;15:727.

Huang P, Zhou X, Zheng M, Yu Y, Jin G, Zhang S. Regulatory T cells are associated with the tumor immune microenvironment and immunotherapy response in triple-negative breast cancer. Front Immunol. 2023;14:1263537.

Nursyirwan SA, Abdullah M, Sulaiman A, et al. Assessment of circulating tumor cells in colorectal cancer as an adjunctive non- invasive diagnostic method. Acta Med Indones – Indones J Intern Med. 2023;55(4):385-95.

Tenggara J, Rachman A, Prihartono J, et al. The association of immune cell infiltration with metastasis location in de novo metastatic triple negative breast cancer: A multicenter cross-sectional study in Indonesia. Acta Med Indones – Indones J Intern Med. 2023;55(4):376-84.

Andayani YD, Saleh I, Sudoyo A, et al. Effect of extra-virgin olive oil on hand foot syndrome and hs-CRP in patients receiving Capecitabine: A randomized trial. Acta Med Indones-Indones J Intern Med. 2023;55(4):396-402.


Full Text: PDF

Refbacks

  • There are currently no refbacks.


Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.